Circassia Expanding FeNO Asthma Testing into Primary Care
Asthma FeNO testing will be available in more US primary care settings as the result of a new national distribution model for Circassia Inc's NIOX Vero FeNO testing device.
Tag: Circassia Aerocrine
All
Latest
Circassia Expanding FeNO Asthma Testing into Primary Care
Asthma FeNO testing will be available in more US primary care settings as the result of a new national distribution model for Circassia Inc’s NIOX Vero FeNO testing device.
Read MoreCOPD: No Added Cardiovascular Risk for Tudorza
Aclidinium reduced acute exacerbations of COPD but did not increase risk of major adverse cardiovascular events, according to a study published in JAMA.
Read MoreFDA Approves Tudorza Pressair sNDA for COPD
The US FDA has expanded Tudorza Pressair’s (aclidinium bromide inhalation powder) approval to include data on its ability to reduce acute exacerbations of COPD.
Read More
FDA Approves Duaklir Fixed-dose LAMA/LABA for COPD
The US FDA has approved twice-daily Duaklir, a fixed-dose combination LAMA/LABA for the maintenance treatment of COPD, according to manufacturer Circassia Pharmaceuticals.
Read More
Circassia Acquires US Rights to AirNOvent
Circassia Pharmaceuticals is acquiring exclusive commercialization rights to nitric oxide product AirNOvent in the US and China from from AIT Therapeutics.
Read More
Aerocrine Receives Clearance for FeNO Device in Japan
The use of Aerocrine’s FeNO-measuring device NIOX VERO as a tool for assessing patients with allergic airway inflammation has been cleared by Japanese health authorities.
Read More
Major US Insurance Provider to Cover FeNO Test For Asthma
Health Care Service Corporation will begin covering FeNO testing for asthma diagnosis and management effective April 1, 2014, according to a press announcement by Aerocrine.
Read More